Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

490.25 -1.37 (-0.28%)
Streaming Delayed Price Updated: 11:00 AM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 168,640
Open 491.33
Bid (Size) 489.63 (4)
Ask (Size) 490.43 (4)
Prev. Close 491.62
Today's Range 489.04 - 495.23
52wk Range 340.02 - 491.76
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Check Out What Whales Are Doing With VRTX
Via Benzinga
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. 
Via InvestorPlace

Performance

YTD
+19.31%
+19.31%
1 Month
+1.44%
+1.44%
3 Month
+23.31%
+23.31%
6 Month
+15.69%
+15.69%
1 Year
+43.46%
+43.46%

More News

Read More
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Via Talk Markets
3 No-Brainer Stocks to Buy in July
Via The Motley Fool
3 Pharma Stocks Already Ushering in the Next Biotech Boom
Via InvestorPlace
Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).
Via The Motley Fool
Why the quality investor may take a look at NASDAQ:VRTX.
Via Chartmill
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
Via Benzinga
The 3 Best Biotech Stocks to Buy in July 2024
Via InvestorPlace
1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever
Via The Motley Fool
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
Via The Motley Fool
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Via The Motley Fool
3 Top-Rated Gene Editing Stocks Actually Making Money
Via InvestorPlace
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Via MarketBeat
Topics ETFs
Exposures COVID-19
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Via InvestorPlace
Vertex to Announce Second Quarter 2024 Financial Results on August 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Breakout Biotech Stocks on Track to Double by 2032
Via InvestorPlace
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Via The Motley Fool
2 Superior Growth Stocks to Buy if You Have $1,000 Right Now
Via The Motley Fool
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
2 Healthcare Stocks That Are Screaming Buys in June
Via The Motley Fool
You’ve Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.
Via InvestorPlace
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.